Activity from announced rounds
RA Capital Management founds, funds and scales companies in healthcare and planetary health, combining scientific research with capital from seed through public-market financings.
Its TechAtlas research platform informs investment decisions through detailed scientific and market analysis. Raven, its healthcare incubator, works on originating and co-creating companies, giving researchers a route from a scientific idea to a funded business.
Blackbird provides a clinical development accelerator alongside the investment platform. These capabilities are relevant for founders who need to design a development programme and reach clinical milestones, as well as finance laboratory or commercial work.
Circle Pharma discovers macrocycle medicines for cancer and other serious diseases using its MXMO platform, which combines computational, structure-based design with synthetic chemistry to create cell-permeable compounds against difficult protein targets. Its lead programs are investigational and at discovery or preclinical stages.
A clinical-stage immunotherapy company is advancing an engineered CTLA-4 antibody for earlier cancer treatment.
Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.
Typewriter Therapeutics is developing an all-RNA gene-writing platform that inserts therapeutic genes at a defined genomic site without viral vectors or double-strand DNA breaks. Its programs target in vivo engineered CAR-T cells and gene insertion for severe genetic diseases, including liver disorders.
Develops oligonucleotide therapeutics targeting chronic hepatitis B
Clinical-stage immunotherapies targeting pathogenic cytotoxic T cells in autoimmune disease.
Develops human-derived antibody therapeutics for atopic dermatitis and inflammatory disease
Develops fungal genome-derived therapeutics for organ transplant rejection
Develops treatments for serious respiratory diseases
Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD
Develops broad-spectrum antiviral prophylactic therapies for respiratory infections
Develops hormonal and non-hormonal male contraceptives for men and couples globally
Clinical-stage company developing neonatal cardiac progenitor cell therapies for Duchenne-associated cardiomyopathy
Develops highly targeted, small molecule medicines for cancer and rare diseases
Provides CAR-T and other advanced treatment delivery in community outpatient settings
Advancing next-generation therapeutics for migraine and other headache disorders
Developing a next-generation pertussis vaccine candidate BPZE1
Develops modular compact fusion machines for clean energy applications
Develops inhaled therapies for severe respiratory diseases
Develops medicines targeting historically undruggable protein targets in cancer